Catabolic effects of gastric bypass in a diet-induced obese rat model

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 4, 2006, Pages 423-435

  Guijarro, Ana ^a   Kirchner, Henriette ^a   Meguid, Michael M ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Body weight; Cytokines; Gastrointestinal hormones; Neuropeptides; Roux en Y gastric bypass

Indexed keywords

ADIPOCYTOKINE; ALPHA INTERMEDIN; ANOREXIGENIC AGENT; CHOLECYSTOKININ; CORTICOSTERONE; CYTOKINE; GASTROINTESTINAL HORMONE; GHRELIN; GLUCOCORTICOID; INSULIN; INTERLEUKIN 6; LEPTIN; NEUROPEPTIDE; NEUROTRANSMITTER; OREXIN; PEPTIDE YY; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ANOREXIA; APPETITE; BARIATRIC SURGERY; BODY MASS; CACHEXIA; CARCINOMA; CATABOLISM; CORTICOSTEROID BLOOD LEVEL; DIET; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; FOOD INTAKE; HOMEOSTASIS; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPOTHALAMUS; MALABSORPTION; MORBID OBESITY; NEUROENDOCRINE SYSTEM; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; REVIEW; ROUX Y ANASTOMOSIS; STOMACH BYPASS; SURGICAL APPROACH; SURGICAL TECHNIQUE; SWEDEN; UNITED STATES; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; ENERGY INTAKE; GASTRIC BYPASS; OBESITY, MORBID; ORGAN SIZE; PEPTIDE HORMONES; RATS; WEIGHT LOSS;

EID: 33746189656     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000232903.04910.7b     Document Type: Review

References (131)

1. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724-1737.
2. Meguid MM, Ramos EJ, Suzuki S, et al. A surgical rat model of human Roux-en-Y gastric bypass. J Gastrointest Surg 2004; 8:621-630.
3. Middleton FA, Ramos EJ, Xu Y, et al. Application of genomic technologies: DNA microarrays and metabolic profiling of obesity in the hypothalamus and in subcutaneous fat. Nutrition 2004; 20:14-25.
4. Ramos EJ, Xu Y, Romanova I, et al. Is obesity an inflammatory disease? Surgery 2003; 134:329-335.
5. Romanova IV, Ramos EJ, Xu Y, et al. Neurobiologic changes in the hypothalamus associated with weight loss after gastric bypass. J Am Coll Surg 2004; 199:887-895.
6. Suzuki S, Ramos EJ, Goncalves CG, et al. Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model. Surgery 2005; 138:283-290. Very important study that shows the altered profile of food intake regulating hormones after RYGB. The results contribute to the understanding of mechanisms leading to weight loss.
7. Xu Y, Ramos EJ, Middleton F, et al. Gene expression profiles post Roux-en-Y gastric bypass. Surgery 2004; 136:246-252.
8. Guijarro A, Laviano A, Meguid MM. Hypothalamic integration of immune function and metabolism. In: Kalsbeek A, Fliers E, Hofman MA, et al., editors. Hypothalamic integration of energy metabolism, progress in brain research. Amsterdam: Elsevier; 2006. pp. 212-228. This review illustrates how the immune and neuroendocrine systems cross talk to regulate metabolism at peripheral and central levels in both physiological and pathological states, including infectious process, cachexia and obesity.
9. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-787.
10. Lazar MA. How obesity causes diabetes: not a tall tale. Science 2005; 307:373-375. In this short viewpoint the parallel evolution of obesity and type 2 diabetes mellitus is described, as well as the close relationship between the pathogenesis of these diseases.
11. Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA 2002; 288:2793-2796.
12. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723-1727.
13. O'Brien PE, Dixon JB. The extent of the problem of obesity. Am J Surg 2002; 184:4S-8S.
14. National Health and Nutrition Examination Survey [NHANES] III. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, Maryland; 1994.
15. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003; 299:853-855.
16. Brolin RE, LaMarca LB, Kenler HA, Cody RP. Malabsorptive gastric bypass in patients with superobesity. J Gastrointest Surg 2002; 6:195-203.
17. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89:2608-2615.
18. Meguid MMMP, Munshi IAM. Accelerated growth of bariatric surgery with the introduction of minimally invasive surgery: invited critique. Arch Surg 2005; 140:1203.
19. Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA 2005; 294:1909-1917. This study evaluates the nationwide (USA) trend in weight loss surgery, providing detailed patient characteristics including gender differences and financial state insurance quality. Further, it gives information about the clinical outcome after the surgical procedures.
20. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683-2693.
21. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346:1623-1630.
22. Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res 2004; 12:346-350.
23. Xu Y, Ohinata K, Meguid MM, et al. Gastric bypass model in the obese rat to study metabolic mechanisms of weight loss. J Surg Res 2002; 107:56-63.
24. Brolin RL, Robertson LB, Kenler HA, Cody RP. Weight loss and dietary intake after vertical banded gastroplasty and Roux-en-Y gastric bypass. Ann Surg 1994; 220:782-790.
25. Clements RH, Gonzalez QH, Long CI, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004; 70:1-4.
26. Fruhbeck G, Diez CA, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med 2004; 350:308-309.
27. Holdstock C, Engstrom BE, Ohrvall M, et al. Effect of bariatric surgery on adipose tissue regulatory peptides and growth hormone secretion. Asia Pac J Clin Nutr 2004; 13:S41.
28. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90:359-365. One of the first studies which investigated changes in PYY after RYGB in humans. The findings contribute to the understanding of neuroendocrine changes after RYGB.
29. Warde-Kamar J, Rogers M, Flancbaum L, Laferrere B. Calorie intake and meal patterns up to 4 years after Roux-en-Y gastric bypass surgery. Obes Surg 2004; 14:1070-1079.
30. Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243:108-114. In this paper the authors study the meal-stimulated response of gut hormones in patients following RGYB or gastric bypass, allowing a comparison between the mechanisms that operate in each surgery procedure to achieve weight loss. In addition, they study the role of PYY in weight loss reduction in a rat model of jejunointestinal bypass.
31. Gletsu N, Lin E, Khaitan L, et al. Changes in C-reactive protein predict insulin sensitivity in severely obese individuals after weight loss surgery. J Gastrointest Surg 2005; 9:1119-1126.
32. Holdstock C, Lind L, Engstrom BE, et al. CRP reduction following gastric bypass surgery is most pronounced in insulin-sensitive subjects. Int J Obes (Lond) 2005; 29:1275-1280.
33. Muscelli E, Mingrone G, Camastra S, et al. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med 2005; 118:51-57.
34. Fruhbeck G, Diez-Caballero A, Gil MJ, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 2004; 14:606-612.
35. Cummings DE, Frayo RS, Marmonier C, et al. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004; 287:E297-E304.
36. Morinigo R, Casamitjana R, Moize V, et al. Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obes Res 2004; 12:1108-1116.
37. Silvestre V, Ruano M, Dominguez Y, et al. Morbid obesity and gastric bypass surgery: biochemical profile. Obes Surg 2004; 14:1227-1232.
38. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12:962-971.
39. Molina A, Vendrell J, Gutierrez C, et al. Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 2003; 13:615-621.
40. Nadreau E, Baraboi ED, Samson P, et al. Effects of the biliopancreatic diversion on energy balance in the rat. Int J Obes (Lond) 2006; 30:419-429. A timely paper investigating a variety of metabolic changes after biliopancreatic diversion in rats. Because Nadreau et al. measured energy intake and energy expenditure, this study helps us to understand the mechanisms of weight loss after weight loss surgery.
41. Quinn R. Comparing rat's to human's age: how old is my rat in people years? Nutrition 2005; 21:775-777. An essential paper which should be recognized by every researcher who studies rat models. This paper provides insights as to a recurrent question of 'how old is my rat'?
42. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides: mediation of the actions of leptin. Trends Neurosci 1999; 22:62-67.
43. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000; 404:661-671.
44. Druce M, Bloom SR. The regulation of appetite. Arch Dis Child 2006; 91:183-187.
45. Cahill GF Jr. Starvation in man. N Engl J Med 1970; 282:668-675.
46. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin- dependent proteolytic system in skeletal muscle during fasting. Am J Physiol Endocrinol Metab 1993; 264:E668-E676.
47. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332:621-628.
48. Flancbaum L, Choban PS, Bradley LR, Burge JC. Changes in measured resting energy expenditure after Roux-en-Y gastric bypass for clinically severe obesity. Surgery 1997; 122:943-949.
49. Trostler N, Mann A, Zilberbush N, et al. Weight loss and food intake 18 months following vertical banded gastroplasty or gastric bypass for severe obesity. Obes Surg 1995; 5:39-51.
50. Meguid MM, Yang ZJ, Laviano A. Meal size and number: relationship to dopamine levels in the ventromedial hypothalamic nucleus. Am J Physiol Regul Integr Comp Physiol 1997; 272:R1925-R1930.
51. Meguid MM, Yang ZJ, Gleason JR. The gut-brain brain-gut axis in anorexia: toward an understanding of food intake regulation. Nutrition 1996; 12:S57-S62.
52. Meguid MM, Yang ZJ, Gleason JR, Kubota A. Differential feeding patterns induced by tumor growth and by TPN. Nutrition 1999; 15:555-562.
53. Laviano A, Meguid MM, Gleason JR, Rossi-Fanelli F. VMN/LHA functional inhibition in tumor-bearing rats suggests hypothalamic involvement in cancer anorexia. Nutr Neurosci 2002; 5:443-456.
54. Valle A, Catala-Niell A, Colom B, et al. Sex-related differences in energy balance in response to caloric restriction. Am J Physiol Endocrinol Metab 2005; 289:E15-E22. Complete and interesting study of the sex-related differences in energy balance in response to caloric restriction, with females shown to deactivate facultative thermogenesis to a greater degree than males.
55. Greenberg JA, Boozer CN. Metabolic mass, metabolic rate, caloric restriction, and aging in male Fischer 344 rats. Mech Ageing Dev 2000; 113:37-48.
56. Canas R, Romero JJ, Baldwin RL. Maintenance energy requirements during lactation in rats. J Nutr 1982; 112:1876-1880.
57. Foster DO, Frydman ML. Tissue distribution of cold-induced thermogenesis in conscious warm- or cold-acclimated rats reevaluated from changes in tissue blood flow: the dominant role of brown adipose tissue in the replacement of shivering by nonshivering thermogenesis. Can J Physiol Pharmacol 1979; 57:257-270.
58. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548-2556.
59. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21:697-738.
60. Marin P, Andersson B, Ottosson M, et al. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism 1992; 41:1242-1248.
61. Fain JN, Bahouth SW, Madan AK. TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 2004; 28:616-622.
62. Banerjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med 2003; 81:218-226.
63. Bouchard C, Tremblay A, Despres JP, et al. The response to long-term overfeeding in identical twins. N Engl J Med 1990; 322:1477-1482.
64. Zamboni M, Armellini F, Muller D, et al. Methodological and clinical aspects of subcutaneous fat distribution. In: Angel, A, Anderson, H, Bouchard, C, et al., editors. Progress in obesity research: Proceedings of the Seventh International Congress on Obesity, Toronto, Canada, 20-25 August 1994. London: John Libbey & Company; 1996. pp. 145-150.
65. Zamboni M, Armellini F, Turcato E, et al. Effect of regain of body weight on regional body fat distribution: comparison between pre- and postmenopausal obese women. Obes Res 1996; 4:555-560.
66. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115:911-919. This review summarizes the mechanisms of action and the role played by the adipokines and cytokines in obesity, diabetes and inflammation.
67. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19:525-546.
68. Curat CA, Miranville A, Sengenes C, et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004; 53:1285-1292.
69. Sainsbury A, Schwarzer C, Couzens M, Herzog H. Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes 2002; 51:3420-3427.
70. Williams G, Bing C, Cai XJ, et al. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 2001; 74:683-701.
71. Blaha V, Yang ZJ, Meguid MM, et al. Ventromedial nucleus of hypothalamus is related to the development of cancer-induced anorexia: in vivo microdialysis study. Acta Medica (Hradec Kralove) 1998; 41:3-11.
72. Makarenko IG, Meguid MM, Gatto L, et al. Normalization of hypothalamic serotonin (5-HT 1B) receptor and NPY in cancer anorexia after tumor resection: an immunocytochemical study. Neurosci Lett 2005; 383:322-327.
73. Meguid MM, Ramos EJ, Laviano A, et al. Tumor anorexia: effects on neuropeptide Y and monoamines in paraventricular nucleus. Peptides 2004; 25:261-266.
74. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 1997; 349:1210-1213.
75. Glass AR, Burman KD, Dahms WT, Boehm TM. Endocrine function in human obesity. Metabolism 1981; 30:89-104.
76. de Jong EC, Vieira PL, Kalinski P, Kapsenberg ML. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. J Leukoc Biol 1999; 66:201-204.
77. Caro JF, Sinha MK, Kolaczynski JW, et al. Leptin: the tale of an obesity gene. Diabetes 1996; 45:1455-1462.
78. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1:1155-1161.
79. Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab 1996; 81:3419-3423.
80. Trayhurn P, Thomas ME, Duncan JS, Rayner DV. Effects of fasting and refeeding on ob gene expression in white adipose tissue of lean and obese (oblob) mice. FEBS Lett 1995; 368:488-490.
81. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79-83.
82. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108:1875-1881.
83. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 2002; 99:16309-16313.
84. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
85. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004; 303:1195-1198.
86. Ramos EJ, Suzuki S, Marks D, et al. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004; 7:427-434.
87. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994; 91:4854-4858.
88. Zhang HH, Halbleib M, Ahmad F, et al. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 2002; 51:2929-2935.
89. Trujillo ME, Sullivan S, Harten I, et al. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 2004; 89:5577-5582.
90. van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003; 88:3005-3010.
91. Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8:75-79.
92. Wallenius K, Wallenius V, Sunter D, et al. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 2002; 293:560-565.
93. Havel PJ. Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med (Maywood) 2001; 226:963-977.
94. Borg CM, le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006; 93:210-215. An important study investigating the prospective changes in gut hormones and metabolic indices after RYGB. The authors suggest gut adaptation and the consequent graded rise in the levels of gut hormones that promote satiety account for the lack of the expected increase in food intake.
95. Abstracts of the 2003 NAASO (North American Association for the Study of Obesity) annual meeting. October 11-15, 2003. Ft. Lauderdale, Florida, USA. Obes Res 2003; 11 (Suppl).
96. Geloneze B, Tambascia MA, Pilla VF, et al. Ghrelin: a gut-brain hormone: effect of gastric bypass surgery. Obes Surg 2003; 13:17-22.
97. Leonetti F, Silecchia G, Iacobellis G, et al. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab 2003; 88:4227-4231.
98. Tritos NA, Mun E, Bertkau A, et al. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 2003; 11:919-924.
99. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120:337-345.
100. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141:4255-4261.
101. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-430.
102. Gualillo O, Caminos J, Blanco M, et al. Ghrelin, a novel placental-derived hormone. Endocrinology 2001; 142:788-794.
103. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin: a hormone with multiple functions. Front Neuroendocrinol 2004; 25:27-68.
104. Masuda Y, Tanaka T, Inomata N, et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000; 276:905-908.
105. Mori K, Yoshimoto A, Takaya K, et al. Kidney produces a novel acylated peptide, ghrelin. FEBS Lett 2000; 486:213-216.
106. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941-948.
107. Bilchik AJ, Hines OJ, Zinner MJ, et al. Peptide YY augments postprandial small intestinal absorption in the conscious dog. Am J Surg 1994; 167:570-574.
108. Bilchik AJ, Hines OJ, Ashley SW, et al. Peptide YY immunoneutralization inhibits meal-induced absorption in vivo. Surgery 1994; 116:1153-1157.
109. Liu CD, Aloia T, Adrian TE, et al. Peptide YY: a potential proabsorptive hormone for the treatment of malabsorptive disorders. Am Surg 1996; 62:232-236.
110. Wiren M, Adrian TE, Arnelo U, et al. An increase in mucosal insulin-like growth factor II content in postresectional rat intestine suggests autocrine or paracrine growth stimulation. Scand J Gastroenterol 1998; 33:1080-1086.
111. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(S-36) physiologically inhibits food intake. Nature 2002; 418:650-654.
112. Pittner RA, Moore CX, Bhavsar SP, et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 2004; 28:963-971.
113. 3-36 induces a negative energy balance by reducing food intake and increasing mobilization of fat stores. These effects are relevant for a better understanding of the mechanisms involved in RYGB-induced catabolism and weight loss.
114. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409:194-198.
115. Kamegai J, Tamura H, Shimizu T, et al. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 2000; 141:4797-4800.
116. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411:480-484.
117. Martini AC, Fernandez-Fernandez R, Tovar S, et al. Comparative analysis of the effects of ghrelin and un-acylated ghrelin upon luteinizing hormone secretion in male rats. Endocrinology 2006; 147:2374-2382.
118. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407:908-913.
119. Wang Z, Zhou YT, Kakuma T, et al. Leptin resistance of adipocytes in obesity: role of suppressors of cytokine signaling. Biochem Biophys Res Commun 2000; 277:20-26.
120. Hanada T, Toshinai K, Kajimura N, et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 2003; 301:275-279.
121. Hanada T, Toshinai K, Date Y, et al. Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. Metabolism 2004; 53:84-88.
122. Wise PM, Dubal DB, Wilson ME, et al. Minireview: neuroprotective effects of estrogen: new insights into mechanisms of action. Endocrinology 2001; 142:969-973.
123. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104:1430-1435.
124. Tanaka M, Naruo T, Nagai N, et al. Habitual binge/purge behavior influences circulating ghrelin levels in eating disorders. J Psychiatr Res 2003; 37:17-22.
125. Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003; 9:774-778.
126. Makarenko IG, Meguid MM, Gatto L, et al. Decreased NPY innervation of the hypothalamic nuclei in rats with cancer anorexia. Brain Res 2003; 961:100-108.
127. Makarenko IG, Meguid MM, Gatto L, et al. Hypothalamic 5-HT1 B-receptor changes in anorectic tumor bearing rats. Neurosci Lett 2005; 376:71-75.
128. Currie PJ. Integration of hypothalamic feeding and metabolic signals: focus on neuropeptide Y. Appetite 2003; 41:335-337.
129. Dryden S, Wang Q, Frankish HM, et al. The serotonin (5-HT) antagonist methysergide increases neuropeptide Y (NPY) synthesis and secretion in the hypothalamus of the rat. Brain Res 1995; 699:12-18.
130. Grill HJ, Ginsberg AB, Seeley RJ, Kaplan JM. Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight. J Neurosci 1998; 18:10128-10135.
131. Martin NM, Smith KL, Bloom SR, Small CJ. Interactions between the melanocortin system and the hypothalamo-pituitary-thyroid axis. Peptides 2006; 27:333-339.